W.J. Hoogenraad

3.8k total citations · 2 hit papers
23 papers, 2.8k citations indexed

About

W.J. Hoogenraad is a scholar working on Cancer Research, Oncology and Pathology and Forensic Medicine. According to data from OpenAlex, W.J. Hoogenraad has authored 23 papers receiving a total of 2.8k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Cancer Research, 11 papers in Oncology and 10 papers in Pathology and Forensic Medicine. Recurrent topics in W.J. Hoogenraad's work include Breast Cancer Treatment Studies (17 papers), Breast Lesions and Carcinomas (10 papers) and Breast Implant and Reconstruction (4 papers). W.J. Hoogenraad is often cited by papers focused on Breast Cancer Treatment Studies (17 papers), Breast Lesions and Carcinomas (10 papers) and Breast Implant and Reconstruction (4 papers). W.J. Hoogenraad collaborates with scholars based in Netherlands, France and Belgium. W.J. Hoogenraad's co-authors include Alain Fourquet, Harry Bartelink, Laurence Collette, M. Piérart, J.J. Jager, H. Struikmans, Philip Poortmans, Jean-Claude Horiot, Walter Van den Bogaert and Carla C. Wárlám-Rodenhuis and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Cancer.

In The Last Decade

W.J. Hoogenraad

22 papers receiving 2.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Impact of a Higher Radiation Dose on Local Control and Survival in Breast-Conserving Therapy of Early Breast Cancer: 10-Year Results of the Randomized Boost Versus No Boost EORTC 22881-10882 Trial

2007 722 citations Harry Bartelink, Jean-Claude Horiot et al. Journal of Clinical Oncology profile →
Recurrence Rates after Treatment of Breast Cancer with Standard Radiotherapy with or without Additional Radiation

2001 693 citations Harry Bartelink, Jean-Claude Horiot et al. New England Journal of Medicine profile →

Peers

Countries citing papers authored by W.J. Hoogenraad

Since Specialization

Citations

This map shows the geographic impact of W.J. Hoogenraad's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by W.J. Hoogenraad with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites W.J. Hoogenraad more than expected).

Fields of papers citing papers by W.J. Hoogenraad

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by W.J. Hoogenraad. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by W.J. Hoogenraad. The network helps show where W.J. Hoogenraad may publish in the future.

Co-authorship network of co-authors of W.J. Hoogenraad

This figure shows the co-authorship network connecting the top 25 collaborators of W.J. Hoogenraad. A scholar is included among the top collaborators of W.J. Hoogenraad based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with W.J. Hoogenraad. W.J. Hoogenraad is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Predictors of the risk of fibrosis at 10 years after breast conserving therapy for early breast cancer – A study based on the EORTC trial 22881–10882 ‘boost versus no boost’ 2008 ·European Journal of Cancer ·Sandra Collette, Laurence Collette, Tom Budiharto, Jean-Claude Horiot, Philip Poortmans, H. Struikmans, Walter Van den Bogaert, Alain Fourquet, J.J. Jager, W.J. Hoogenraad, Rolf‐Peter Mueller, John M. Kurtz, D.A.L. Morgan, Jean‐Bernard Dubois, E. Salamon, R.O. Mirimanoff, M. Bolla, (unknown), Carla C. Wárlám-Rodenhuis, Harry Bartelink	157
2	Impact of the boost dose of 10Gy versus 26Gy in patients with early stage breast cancer after a microscopically incomplete lumpectomy: 10-year results of the randomised EORTC boost trial 2008 ·Radiotherapy and Oncology ·Philip Poortmans, Laurence Collette, Jean-Claude Horiot, (unknown), Alain Fourquet, Abraham Kuten, Evert M. Noordijk, W.J. Hoogenraad, René‐Olivier Mirimanoff, M. Piérart, Erik Van Limbergen, Harry Bartelink	107
3	The addition of a boost dose on the primary tumour bed after lumpectomy in breast conserving treatment for breast cancer. A summary of the results of EORTC 22881-10882 “boost versus no boost” trial 2008 ·Cancer/Radiothérapie ·Philip Poortmans, Laurence Collette, Harry Bartelink, H. Struikmans, (unknown), Alain Fourquet, J.J. Jager, W.J. Hoogenraad, (unknown), (unknown), M. Bolla, M. van der Hulst, Carla C. Wárlám-Rodenhuis, M. Piérart, (unknown)	76
4	The impact of a boost dose on the local recurrence rate in high risk patients after breast conserving therapy – results from the EORTC boost-no boost trial 2008 ·European Journal of Cancer Supplements ·Helen Jones, Ninja Antonini, Laurence Collette, Alain Fourquet, W.J. Hoogenraad, J.J. Jager, Hans Peterse, P. Poortmans, H. Struikmans, Harry Bartelink	0
5	The Impact of Boost Dose and Margins on the Local Recurrence Rate in Breast Conserving Therapy: Results From the EORTC Boost-No Boost Trial 2007 ·International Journal of Radiation OncologyBiologyPhysics ·Helen Jones, Ninja Antonini, (unknown), Alain Fourquet, W.J. Hoogenraad, W. Van den Bogaert, J.J. Jager, P. Poortmans, H. Struikmans, Harry Bartelink	6
6	Impact of a Higher Radiation Dose on Local Control and Survival in Breast-Conserving Therapy of Early Breast Cancer: 10-Year Results of the Randomized Boost Versus No Boost EORTC 22881-10882 Trial breakdown → 2007 ·Journal of Clinical Oncology ·Harry Bartelink, Jean-Claude Horiot, Philip Poortmans, H. Struikmans, Walter Van den Bogaert, Alain Fourquet, J.J. Jager, W.J. Hoogenraad, S.B. Oei, Carla C. Wárlám-Rodenhuis, M. Piérart, Laurence Collette	722
7	Effect of age and radiation dose on local control after breast conserving treatment: EORTC trial 22881-10882 2006 ·Radiotherapy and Oncology ·Ninja Antonini, Heather Jones, Jean Claude Horiot, Philip Poortmans, H. Struikmans, Walter Van den Bogaert, I. Barillot, Alain Fourquet, J.J. Jager, W.J. Hoogenraad, Laurence Collette, M. Piérart, Guus Hart, Harry Bartelink	120
8	The influence of the boost technique on local control in breast conserving treatment in the EORTC ‘boost versus no boost’ randomised trial 2004 ·Radiotherapy and Oncology ·Philip Poortmans, Harry Bartelink, Jean-Claude Horiot, H. Struikmans, Walter Van den Bogaert, Alain Fourquet, J.J. Jager, W.J. Hoogenraad, Patrick Rodrigus, Carla C. Wárlám-Rodenhuis, Laurence Collette, M. Piérart	114
9	The influence of the boost technique on local control in breast conserving treatment in the EORTC ‘boost versus no boost’ trial 2004 ·European Journal of Cancer Supplements ·P. Poortmans, H. Bartelink, (unknown), H. Struikmans, W. Van den Bogaert, Alain Fourquet, J.J. Jager, W.J. Hoogenraad, Patrick Rodrigus, Carla C. Wárlám-Rodenhuis, Laurence Collette, M. Piérart	18
10	Can patient-, treatment- and pathology-related characteristics explain the high local recurrence rate following breast-conserving therapy in young patients? 2003 ·European Journal of Cancer ·Conny Vrieling, Laurence Collette, Alain Fourquet, W.J. Hoogenraad, Jean-Claude Horiot, J.J. Jager, S.B. Oei, Hans Peterse, M. Piérart, P. Poortmans, H. Struikmans, W. Van den Bogaert, Harry Bartelink	130
11	Minder lokale recidieven van borstkanker door extra lokale bestralingsdosis na mammasparende chirurgie: 5-jaarsresultaten van een klinische trial 2002 ·Nederlandsch tijdschrift voor geneeskunde/Nederlands tijdschrift voor geneeskunde/NTvG-databank ·H. Bartelink, P Poortmans, (unknown), Jacques Borger, (unknown), W.J. Hoogenraad, W. Van den Bogaert, I. Barillot, Alain Fourquet, Laurence Collette, M. Piérart, J.C. Horiot	1
12	Recurrence Rates after Treatment of Breast Cancer with Standard Radiotherapy with or without Additional Radiation breakdown → 2001 ·New England Journal of Medicine ·Harry Bartelink, Jean-Claude Horiot, Philip Poortmans, H. Struikmans, Walter Van den Bogaert, I. Barillot, Alain Fourquet, Jacques Borger, J.J. Jager, W.J. Hoogenraad, Laurence Collette, M. Piérart	693
13	The influence of patient, tumor and treatment factors on the cosmetic results after breast-conserving therapy in the EORTC ‘boost vs. no boost’ trial 2000 ·Radiotherapy and Oncology ·Conny Vrieling, Laurence Collette, Alain Fourquet, W.J. Hoogenraad, J.C. Horiot, J.J. Jager, M. Piérart, Philip Poortmans, H. Struikmans, B. Maat, Erik Van Limbergen, Harry Bartelink	250
14	The influence of the boost in breast-conserving therapy on cosmetic outcome in the eortc “boost versus no boost” trial 1999 ·International Journal of Radiation OncologyBiologyPhysics ·Conny Vrieling, Laurence Collette, Alain Fourquet, W.J. Hoogenraad, Jean-Claude Horiot, J.J. Jager, M. Piérart, Philip Poortmans, H. Struikmans, (unknown), Emmanuel van der Schueren, Harry Bartelink	128
15	Results of a phase II trial of epirubicin and cisplatin (EP) before and after irradiation and 5-fluorouracil in locally advanced pancreatic cancer: An EORTC GITCCG study 1996 ·European Journal of Cancer ·(unknown), W.J. Hoogenraad, (unknown), A. Lusinchi, Babs G. Taal, C.H.N. Veenhof, Alexander de Graeff, Thierry Conroy, Desmond Curran, Tarek Sahmoud, J. Wils	16
16	Patient population analysis in eortc trial 22881/10882 on the role of a booster dose in breast-conserving therapy 1994 ·European Journal of Cancer ·(unknown), W. Van den Bogaert, M. van Glabbeke, M. Piérart, Harry Bartelink, Jean-Claude Horiot, Alain Fourquet, H. Struikmans, Han Hamers, R.-P. Müller, W.J. Hoogenraad, J.J. Jager, Emmanuel van der Schueren	22
17	Accelerated fractionation radiotherapy for laryngeal cancer, acute, and late toxicity 1992 ·International Journal of Radiation OncologyBiologyPhysics ·Johannes H.A.M. Kaanders, W.A.J. van Daal, W.J. Hoogenraad, Albert J. van der Kogel	50
18	Local control in t3 laryngeal cancer treated with radical radiotherapy, time dose relationship: the concept of nominal standard dose and linear quadratic model 1991 ·International Journal of Radiation OncologyBiologyPhysics ·C. Terhaard, A.B.M.F. Karim, W.J. Hoogenraad, R.E. Tjho‐Heslinga, Ronald B. Keus, D. M. Mehta, (unknown), G.J. Hordijk	23
19	Postoperative radiation therapy for rectal cancer. An interim analysis of a prospective, randomized multicenter trial in the Netherlands 1991 ·Cancer ·A. D. Treurniet-Donker, Wim L.J. van Putten, J. C. J. Wereldsma, E. D. M. Bruggink, W.J. Hoogenraad, Jan A. Roukema, A. Snijders-Keilholz, Willem S. Meijer, J.H. Meerwaldt, Arendjan Wijnmaalen, Th. Wiggers	103
20	Phase II trial of 5-fluorouracil, adriamycin and cisplatin (FAP) followed by radiation and 5-fluorouracil in locally advanced pancreatic cancer 1989 ·Cancer Chemotherapy and Pharmacology ·D. J. Th. Wagener, Q.G.C.M. van Hoesel, Sing Hiem Yap, W.J. Hoogenraad, Th. Wobbes, S P Strijk	16

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact